EPZM News and Press, Epizyme Inc. From 12/09/19

December 9, 2019 Palm Beach, FL –December 9, 2019 – One of the latest market reports in the published by Credence Research, Inc. shows that the Multiple Myeloma Treatment market, which was valued at USD $8,398.3 Mn in 2016, is expected to reach USD $21,221.8 Mn ...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 134 weeks of public selections as part of this ongoing live forward-testing. In...

Results  from an open-label Phase 2 clinical trial evaluating Epizyme's (NASDAQ: EPZM ) tazemetostat in follicular lymphoma (FL) patients, with or without EZH2 activating mutations, showed a treatment benefit. The data were presented at ASH in Orlando. More news on: Epizyme, Inc.,...

NDA Submission for Accelerated Approval of Tazemetostat for Patients with Relapsed or Refractory Follicular Lymphoma on Track for December 2019 Epizyme, Inc . (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today reported positive, mature ...

Amedisys (NASDAQ: AMED ) initiated with Market Perform rating and $170 (3% upside) price target at BMO. More news on: Amedisys, Inc., Athenex, Inc., Gossamer Bio, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Epizyme (NASDAQ: EPZM ) is up 2.6% postmarket after its last cautious analyst holdout joined others in the bull column. More news on: Epizyme, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Epizyme ( EPZM -5.9% ) slips on average volume as broad market selling weighs on shares. The stock had rallied over  70%  since early October before today's action. More news on: Epizyme, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Epizyme, Inc . (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) is scheduled to review data supporting the company’s New Drug ...

Introduction to the Positive/Negative Forensic Value Stock Selections This quantitative study continues a series of multi-year test now using the top four forensic algorithms applied to detect bankruptcy risk, earnings manipulation, and financial irregularities. This forward testing study co...

Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 131 weeks of public selections as part of this ongoing live forward-testing. In...